Ustekinumab as Induction and Maintenance Therapy for Crohn’s DiseaseBrian G. Feagan, Paul Rutgeerts, Christopher Gasink et al.|New England Journal of Medicine|2016Cited by 1.8k
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's DiseaseWilliam J. Sandborn, Brian G. Feagan, Christopher Gasink et al.|New England Journal of Medicine|2012Cited by 1.1k
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trialBruce E. Sands, Olga Fedorishina, Peter M. Irving et al.|The Lancet|2022Cited by 301
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's DiseaseOmoniyi J. Adedokun, William J. Sandborn, Zhenhua Xu et al.|Gastroenterology|2018Cited by 253
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn’s DiseaseStephen B. Hanauer, Subrata Ghosh, William J. Sandborn et al.|Journal of Crohn s and Colitis|2019Cited by 211